Summary

The sepsis diagnostics market is projected to reach USD 1.22 billion by 2031, up from USD 0.83 billion in 2026, at a CAGR of 7.9%. The global sepsis diagnostics market is expected to grow steadily over the forecast period, driven by the rising burden of sepsis and bloodstream infections, increasing ICU admissions, growing demand for rapid pathogen identification, and rising adoption of molecular diagnostics, automated microbiology platforms, immunoassays, and biomarker-based testing. Market growth is further supported by the increasing focus on antimicrobial stewardship programs, the need to reduce diagnostic turnaround time, and the adoption of automated diagnostic workflows in hospital and reference laboratories. However, the high cost of advanced molecular diagnostic platforms, limited reimbursement for novel diagnostic technologies, the clinical complexity of sepsis presentation, workflow integration challenges, and a shortage of trained laboratory personnel are expected to restrain market growth to some extent. Assays & reagent kits accounted for the largest share of the sepsis diagnostics market, by product, in 2025. By product, the sepsis diagnostics market is segmented into blood culture media, assays & reagent kits, instruments, and software. In 2025, assays & reagent kits accounted for the largest market share, driven by their recurring use in blood culture testing, immunoassays, molecular diagnostics, antimicrobial susceptibility testing, and biomarker-based sepsis assessment. Rising demand for pathogen detection kits, PCR-based reagents, syndromic testing panels, inflammatory biomarker assays, and sepsis-related consumables continues to support this segment's dominance. Additionally, the growing adoption of automated and molecular testing platforms across hospitals and reference laboratories is further strengthening demand for assays and reagent kits. Blood culture/microbiology testing accounted for the largest share of the sepsis diagnostics market, by technology, in 2025. By technology, the global sepsis diagnostics market is segmented into blood culture/microbiology testing, immunoassays, molecular diagnostics, flow cytometry, mass spectrometry, and clinical chemistry & blood gas analysis. In 2025, blood culture/microbiology testing accounted for the largest share, reflecting its established role as the standard diagnostic approach for detecting bloodstream infections and supporting antimicrobial susceptibility testing. These technologies are widely used in hospital microbiology laboratories for pathogen detection, organism identification, and therapy guidance. However, molecular diagnostics is expected to grow faster over the forecast period, supported by increasing adoption of PCR/RT-PCR, multiplex PCR panels, microarrays, FISH/PNA-FISH, DNA sequencing, NGS, LAMP, and TMA-based methods for rapid pathogen and resistance marker detection. The Asia Pacific region is projected to grow at the highest CAGR in the sepsis diagnostics market from 2026 to 2031. The sepsis diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, the Asia Pacific region is projected to have the highest CAGR, driven by the rising burden of infectious diseases and bloodstream infections, expanding hospital and ICU infrastructure, rising healthcare expenditure, and growing adoption of automated microbiology and molecular diagnostic platforms. Growth is further supported by improving laboratory capacity, greater awareness of sepsis management, rising demand for rapid diagnostics, and large patient populations across China, Japan, India, South Korea, Australia, and Southeast Asia. List of Companies Profiled in the Report ・Biomérieux ・Becton Dickinson and Company ・Danaher Corporation ・Diasorin S.P.A (Luminex) ・F. Hoffmann-La Roche AG ・Thermo Fisher Scientific, Inc ・Bruker Corporation ・Abbott Laboratories ・Sysmex Corporation ・Siemens Healthineers ・Qiagen ・Quidelortho Corporation ・Shenzhen Mindray Bio-Medical Electronics Co., Ltd. Research Coverage This research report categorizes the sepsis diagnostics market by product, technology, method, pathogen type, test type, sample type, complexity, clinical utility/management pathway, end user, and region. The scope of the report covers detailed information on the major factors influencing the market, including drivers, restraints, opportunities, and challenges. It includes a detailed analysis of key industry players, providing insights into their business overview, product portfolio, key strategies such as product launches, regulatory approvals, collaborations, partnerships, acquisitions, and expansions, as well as recent developments associated with the sepsis diagnostics market. This report also covers a competitive analysis of leading players and emerging companies in the sepsis diagnostics ecosystem. Key Benefits of Buying the Report The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall sepsis diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. The report will enable stakeholders to understand the market pulse and provide information on key market drivers, restraints, opportunities, and challenges. The report provides insights into the following points: ・Analysis of key drivers, including the high incidence of sepsis and bloodstream infections, growing adoption of rapid molecular and syndromic diagnostics, increasing focus on antimicrobial stewardship, and expansion of biomarker-based testing; restraints, including the high cost of advanced molecular diagnostic platforms and limited reimbursement for novel diagnostic technologies; opportunities, including AI-enabled sepsis diagnosis, clinical decision support, next-generation host-response biomarkers, rapid POC testing, and decentralized testing; and challenges, including clinical complexity, heterogeneous sepsis presentation, integration into hospital workflows, and a shortage of trained laboratory personnel ・Product Development/Innovation: Detailed insights into newly launched and emerging sepsis diagnostics products, including automated blood culture systems, molecular diagnostic panels, syndromic testing platforms, immunoassays, biomarker-based tests, mass spectrometry-based microbial identification platforms, antimicrobial susceptibility testing solutions, and AI-enabled clinical decision support tools ・Market Development: Comprehensive information about lucrative markets — the report analyzes the sepsis diagnostics market across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with detailed assessment of major country-level opportunities and adoption trends ・Market Diversification: Comprehensive information on product portfolios, technological developments, regulatory approvals, collaborations, partnerships, acquisitions, geographic expansions, and investments in the sepsis diagnostics market Competitive Assessment: In-depth assessment of market shares, growth strategies, technological capabilities, diagnostic platforms, service offerings, and competitive positioning of leading players, including bioMérieux SA, Becton, Dickinson and Company, Danaher Corporation, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Bruker Corporation, and DiaSorin S.p.A., among others

ページTOPに戻る

Table of Contents

1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.3 STUDY SCOPE 47
1.3.1 MARKETS COVERED & REGIONAL SCOPE 47
1.3.2 INCLUSIONS & EXCLUSIONS 48
1.3.3 YEARS CONSIDERED 49
1.3.4 CURRENCY CONSIDERED 49
1.4 STAKEHOLDERS 49
1.5 SUMMARY OF CHANGES 50
2 EXECUTIVE SUMMARY 51
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 51
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 52
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 53
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 54
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 55
3 PREMIUM INSIGHTS 56
3.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW 56
3.2 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031 57
3.3 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031 57
3.4 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2026 VS. 2031 58
3.5 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2026 VS. 2031 58
3.6 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2026 VS. 2031 59
3.7 SEPSIS DIAGNOSTICS MARKET, SAMPLE TYPE, 2026 VS. 2031 59
3.8 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2026 VS. 2031 60
3.9 SEPSIS DIAGNOSTICS MARKET, CLINICAL UTILITY/MANAGEMENT PATHWAY, 2026 VS. 2031 60
3.10 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031 61
3.11 SEPSIS DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61
4 MARKET OVERVIEW 62
4.1 INTRODUCTION 62
4.2 MARKET DYNAMICS 63
4.2.1 DRIVERS 63
4.2.1.1 High incidence of sepsis and bloodstream infections 63
4.2.1.2 Growing adoption of rapid molecular and syndromic diagnostics 64
4.2.1.3 Increasing focus on antimicrobial stewardship and expansion of biomarker-based testing for early sepsis detection and risk assessment 64
4.2.2 RESTRAINTS 65
4.2.2.1 High cost of advanced molecular diagnostic platforms 65
4.2.2.2 Limited reimbursement for novel sepsis diagnostic technologies 66
4.2.3 OPPORTUNITIES 66
4.2.3.1 AI-enabled sepsis diagnosis and clinical decision support 66
4.2.3.2 Development of next-generation host-response biomarkers 66
4.2.3.3 Growth of rapid POC and decentralized testing 67
4.2.4 CHALLENGES 67
4.2.4.1 Clinical complexity and heterogeneous presentation of sepsis 67
4.3 UNMET NEEDS & WHITE SPACES 68
4.3.1 UNMET NEEDS IN SEPSIS DIAGNOSTICS MARKET 68
4.3.2 WHITE SPACE OPPORTUNITIES 69
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 70
4.4.1 INTERCONNECTED MARKETS 70
4.4.2 CROSS-SECTOR OPPORTUNITIES 72
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 73
4.5.1 KEY MOVES & STRATEGIC FOCUS 73
5 INDUSTRY TRENDS 75
5.1 PORTER’S FIVE FORCES ANALYSIS 75
5.1.1 BARGAINING POWER OF SUPPLIERS 76
5.1.2 BARGAINING POWER OF BUYERS 76
5.1.3 THREAT OF NEW ENTRANTS 76
5.1.4 THREAT OF SUBSTITUTES 77
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 77
5.2 MACROECONOMIC OUTLOOK 77
5.2.1 INTRODUCTION 77
5.2.2 GDP TRENDS & FORECAST 77
5.2.3 TRENDS IN GLOBAL SEPSIS DIAGNOSTICS INDUSTRY 81
5.3 SUPPLY CHAIN ANALYSIS 81
5.4 VALUE CHAIN ANALYSIS 83
5.5 ECOSYSTEM ANALYSIS 87
5.5.1 SEPSIS DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 88
5.6 PRICING ANALYSIS 89
5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024–2026 89
5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2024–2026 90
5.7 TRADE ANALYSIS 91
5.7.1 IMPORT SCENARIO (HS CODE 3822) 92
5.7.2 EXPORT SCENARIO (HS CODE 3822) 93
5.8 KEY CONFERENCES & EVENTS, 2026–2027 93
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
5.10 INVESTMENT & FUNDING SCENARIO 95
5.11 IMPACT OF US TARIFFS—SEPSIS DIAGNOSTICS MARKET 96
5.11.1 INTRODUCTION 96
5.11.2 KEY TARIFF RATES 96
5.11.3 PRICE IMPACT ANALYSIS 97
5.11.4 IMPACT ON REGIONS 97
5.11.4.1 North America 97
5.11.4.2 Europe 98
5.11.4.3 Asia Pacific 98
5.11.5 IMPACT ON END-USE INDUSTRIES 98
5.11.5.1 Hospital and specialty clinics 98
5.11.5.2 Pathology and reference laboratories 98
5.11.5.3 Research laboratories, academic institutes, and CROs 99
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 100
6.1 KEY EMERGING TECHNOLOGIES 100
6.1.1 HOST-RESPONSE DIAGNOSTICS (TRANSCRIPTOMICS & IMMUNE PROFILING) 100
6.1.2 AI-ENABLED AND PREDICTIVE SEPSIS DIAGNOSTICS 100
6.2 COMPLEMENTARY TECHNOLOGIES 100
6.2.1 RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING (RAPID AST) 100
6.2.2 NEXT-GENERATION SEQUENCING (NGS) AND METAGENOMIC SEQUENCING 101
6.3 ADJACENT TECHNOLOGIES 101
6.3.1 CONTINUOUS PATIENT MONITORING & CLINICAL DECISION SUPPORT SYSTEMS (CDSS) 101
6.4 TECHNOLOGY/PRODUCT ROADMAP 101
6.5 PATENT ANALYSIS 103
6.5.1 LIST OF MAJOR PATENTS 104
6.6 FUTURE APPLICATIONS 105
6.7 IMPACT OF AI/GENERATIVE AI ON SEPSIS DIAGNOSTICS MARKET 106
6.7.1 INTRODUCTION 106
6.7.2 TOP USE CASES & MARKET POTENTIAL 107
6.7.3 KEY COMPANIES IMPLEMENTING AI 108
6.7.4 FUTURE OF AI 108
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 109
7.1 REGIONAL REGULATIONS & COMPLIANCE 109
7.1.1 REGULATORY ANALYSIS 109
7.1.1.1 North America 109
7.1.1.1.1 US 109
7.1.1.1.2 Canada 109
7.1.1.2 Europe 109
7.1.1.2.1 Germany 110
7.1.1.2.2 UK 111
7.1.1.2.3 France 111
7.1.1.2.4 Italy 111
7.1.1.3 Asia Pacific 112
7.1.1.3.1 China 112
7.1.1.3.2 Japan 112
7.1.1.3.3 India 112
7.1.1.3.4 Australia 113
7.1.1.4 Latin America 113
7.1.1.4.1 Brazil 114
7.1.1.4.2 Mexico 114
7.1.1.5 Middle East 114
7.1.1.5.1 Africa 114
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 115
7.2 SUSTAINABILITY INITIATIVES 116
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES 116
7.2.1.1 Eco-friendly initiatives 117
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 117
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 119
8.1 DECISION-MAKING PROCESS 119
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 120
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 120
8.2.2 BUYING CRITERIA 121
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 121
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 124
8.5 MARKET PROFITABILITY 124
8.6 REVENUE POTENTIAL 124
8.6.1 COST DYNAMICS 125
9 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT 126
9.1 INTRODUCTION 127
9.2 BLOOD CULTURE MEDIA 127
9.2.1 CONTINUED RELIANCE ON BLOOD CULTURE AS GOLD STANDARD FOR BLOODSTREAM INFECTION DIAGNOSIS SUSTAINS DEMAND 127
9.3 ASSAYS & REAGENT KITS 131
9.3.1 INCREASING ADOPTION OF RAPID MOLECULAR AND BIOMARKER-BASED TESTING DRIVES RECURRING DEMAND FOR ASSAYS AND REAGENT KITS 131
9.4 INSTRUMENTS 135
9.4.1 EXPANSION OF LAB AUTOMATION AND RAPID DIAGNOSTIC PLATFORMS ACCELERATES INVESTMENT IN ADVANCED INSTRUMENTS 135
9.5 SOFTWARE 139
9.5.1 IMPLEMENTATION OF LAB INFORMATICS AND ANTIMICROBIAL STEWARDSHIP SOLUTIONS SUPPORTS SOFTWARE ADOPTION 139
10 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY 143
10.1 INTRODUCTION 144
10.2 BLOOD CULTURE (MICROBIOLOGY TESTING) 145
10.2.1 AS REGULATORY AND CLINICAL GOLD STANDARD, BLOOD CULTURE HOLDS LARGEST MARKET SHARE 145
10.3 IMMUNOASSAYS 148
10.3.1 EXPANDING ADOPTION OF HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS ASSESSMENT AND ANTIMICROBIAL STEWARDSHIP DRIVES MARKET GROWTH 148
10.4 MOLECULAR DIAGNOSTICS 151
10.4.1 PCR 157
10.4.1.1 Widespread hospital adoption of syndromic multiplex panels for rapid pathogen and resistance gene identification to propel market growth 157
10.4.2 MICROARRAYS 160
10.4.2.1 Stable utilization in established blood culture identification workflows supports moderate growth 160
10.4.3 FISH/PNA-FISH 164
10.4.3.1 Retention of rapid Gram stain-adjunct testing in cost-constrained laboratories sustains low-growth utilization amid progressive substitution 164
10.4.4 DNA SEQUENCING & NGS 168
10.4.4.1 Growing clinical interest in culture-independent broad-spectrum pathogen detection drives adoption, constrained by cost and reimbursement barriers 168
10.4.5 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES 171
10.5 FLOW CYTOMETRY 175
10.5.1 GROWING CLINICAL INTEREST IN CELLULAR HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS RISK ASSESSMENT SUPPORTS STEADY MARKET GROWTH 175
10.6 MASS SPECTROMETRY 179
10.6.1 RISING EMPHASIS ON RAPID DIAGNOSTICS, LAB AUTOMATION, AND ANTIMICROBIAL STEWARDSHIP PROPELS ADOPTION 179
10.7 CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS 183
10.7.1 WIDE UTILIZATION OF INFLAMMATORY BIOMARKERS AND RISING ADOPTION OF POC DIAGNOSTICS PROPEL MARKET GROWTH 183
11 SEPSIS DIAGNOSTICS MARKET, BY METHOD 188
11.1 INTRODUCTION 189
11.2 CONVENTIONAL DIAGNOSTICS 190
11.2.1 RELIANCE ON MANUAL MICROBIOLOGICAL AND BIOCHEMICAL WORKFLOWS IN RESOURCE-CONSTRAINED AND LOW-THROUGHPUT SETTINGS SUSTAINS DEMAND 190
11.3 AUTOMATED DIAGNOSTICS 193
11.3.1 GROWING INSTALLATION OF AUTOMATED PLATFORMS TO EXPEDITE TIME-TO-RESULT AND ADDRESS STAFFING SHORTAGES DRIVES SEGMENT GROWTH 193
12 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE 198
12.1 INTRODUCTION 199
12.2 BACTERIAL SEPSIS 200
12.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS 203
12.2.1.1 Rising prevalence of carbapenem-resistant and ESBL-producing organisms driving demand for resistance-marker testing 203
12.2.2 GRAM-POSITIVE BACTERIAL SEPSIS 207
12.2.2.1 Established diagnostic workflows for staphylococcal and enterococcal bloodstream infection sustain stable growth 207
12.3 FUNGAL SEPSIS 211
12.3.1 RISING INCIDENCE OF FUNGAL BLOODSTREAM INFECTIONS DRIVES DEMAND 211
12.4 OTHER PATHOGEN TYPES 214
13 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE 219
13.1 INTRODUCTION 220
13.2 LABORATORY TESTS 220
13.2.1 CENTRALIZATION OF BLOOD CULTURE, MOLECULAR, AND MASS SPECTROMETRY WORKFLOWS WITHIN ACCREDITED HOSPITAL LABORATORIES SUSTAINS THE DOMINANT SHARE 220
13.3 POC TESTS 223
13.3.1 EXPANDING NEAR-PATIENT LACTATE AND BIOMARKER TESTING TO MEET SEPSIS BUNDLE COMPLIANCE TIMELINES DRIVES GROWTH 223
14 SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE 227
14.1 INTRODUCTION 228
14.2 WHOLE BLOOD 228
14.2.1 EMERGENCE OF DIRECT-FROM-BLOOD MOLECULAR TESTING AND WIDESPREAD USAGE OF WHOLE BLOOD SPECIMENS DRIVE MARKET 228
14.3 SERUM 232
14.3.1 SUSTAINED RELIANCE ON SERUM AND PLASMA FOR BIOMARKER-BASED TRIAGE AND ANTIBIOTIC STEWARDSHIP MAINTAINS STABLE GROWTH 232
15 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY 236
15.1 INTRODUCTION 237
15.2 SINGLEPLEX 237
15.2.1 RECURRING VOLUME OF SINGLE-ANALYTE BIOMARKER AND CHEMISTRY TESTING SUSTAINS MARKET SHARE 237
15.3 MULTIPLEX 241
15.3.1 WIDESPREAD ADOPTION OF SYNDROMIC PANELS DELIVERING SIMULTANEOUS PATHOGEN AND RESISTANCE GENE IDENTIFICATION DRIVES GROWTH 241
16 SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY 245
16.1 INTRODUCTION 246
16.2 SEPSIS DIAGNOSIS 246
16.2.1 EXPANDING AVAILABILITY OF ASSAYS AND WIDESPREAD TESTING TO DRIVE MARKET 246
16.3 PATHOGEN IDENTIFICATION 249
16.3.1 ENTRENCHED CULTURE AND IDENTIFICATION WORKFLOWS SUSTAIN SUBSTANTIAL VOLUME 249
16.4 SEPSIS RISK STRATIFICATION 253
16.4.1 RISING DEPLOYMENT OF AUTOMATED SEVERITY SCORING AND CELLULAR HOST-RESPONSE MARKERS INTEGRATED WITH EARLY WARNING SYSTEMS DRIVES HIGH GROWTH 253
16.5 ANTIMICROBIAL STEWARDSHIP SUPPORT 256
16.5.1 INSTITUTIONAL REQUIREMENT FOR STEWARDSHIP AND ESCALATING BURDEN OF ANTIMICROBIAL RESISTANCE TO DRIVE MARKET 256
16.6 PROGNOSIS & OUTCOME PREDICTION 260
16.6.1 LIMITED UTILITY OF PROGNOSTIC INFORMATION CONTINUES TO HINDER DEDICATED ADOPTION 260
17 SEPSIS DIAGNOSTICS MARKET, BY END USER 264
17.1 INTRODUCTION 265
17.2 HOSPITALS & SPECIALTY CLINICS 266
17.2.1 INCREASING BURDEN OF SEPSIS AND GROWING ADOPTION OF RAPID DIAGNOSTIC WORKFLOWS IN ACUTE CARE SETTINGS TO DRIVE MARKET LEADERSHIP 266
17.3 PATHOLOGY & REFERENCE LABORATORIES 269
17.3.1 INCREASING OUTSOURCING OF SPECIALIZED MICROBIOLOGY AND MOLECULAR TESTING SUPPORTS STEADY MARKET GROWTH 269
17.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS 273
17.4.1 EXPANDING SEPSIS BIOMARKER RESEARCH AND DIAGNOSTIC INNOVATION CONTINUE TO SUPPORT LONG-TERM MARKET DEVELOPMENT 273
18 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, (NUMBER OF TESTS IN MILLIONS) 277
18.1 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, (NUMBER OF TESTS IN MILLIONS) 277
19 SEPSIS DIAGNOSTICS MARKET, BY REGION 278
19.1 INTRODUCTION 279
19.2 NORTH AMERICA 279
19.2.1 US 288
19.2.1.1 High burden of sepsis and early adoption of advanced diagnostic technologies drive market leadership 288
19.2.2 CANADA 294
19.2.2.1 Strong public healthcare infrastructure and expanding adoption of advanced microbiology technologies support market growth 294
19.3 EUROPE 299
19.3.1 GERMANY 305
19.3.1.1 Advanced clinical microbiology infrastructure and strong laboratory automation drive market leadership 305
19.3.2 UK 311
19.3.2.1 National sepsis initiatives and NHS investments continue to accelerate adoption of rapid diagnostics 311
19.3.3 FRANCE 316
19.3.3.1 Expansion of hospital microbiology networks and leadership of domestic diagnostic manufacturers drive growth 316
19.3.4 ITALY 321
19.3.4.1 Growing burden of HAIs supports adoption of advanced sepsis diagnostics 321
19.3.5 SWITZERLAND 327
19.3.5.1 Presence of global diagnostic manufacturers and strong healthcare investment support market growth 327
19.3.6 SPAIN 333
19.3.6.1 Increasing healthcare modernization and laboratory automation continue to strengthen market growth 333
19.3.7 REST OF EUROPE 338
19.4 ASIA PACIFIC 344
19.4.1 CHINA 351
19.4.1.1 Rapid healthcare modernization and expanding hospital laboratory infrastructure drive market growth 351
19.4.2 JAPAN 357
19.4.2.1 Advanced healthcare infrastructure and high adoption of innovative diagnostics support market expansion 357
19.4.3 INDIA 362
19.4.3.1 Expanding healthcare infrastructure and rising sepsis burden accelerate adoption of advanced diagnostics 362
19.4.4 SOUTH KOREA 367
19.4.4.1 Government investment in precision medicine and diagnostic innovation drives market expansion 367
19.4.5 AUSTRALIA 372
19.4.5.1 Strong clinical guidelines and high adoption of laboratory automation support market growth 372
19.4.6 REST OF ASIA PACIFIC 378
19.5 LATIN AMERICA 384
19.5.1 BRAZIL 390
19.5.1.1 Growing burden of infectious diseases and expansion of hospital laboratory infrastructure drive market growth 390
19.5.2 MEXICO 396
19.5.2.1 Healthcare modernization and expanding access to advanced diagnostics support market growth 396
19.5.3 REST OF LATIN AMERICA 401
19.6 MIDDLE EAST & AFRICA 407
19.6.1 GCC COUNTRIES 413
19.6.1.1 Healthcare modernization and government investments in advanced diagnostics drive regional growth 413
19.6.2 REST OF MIDDLE EAST & AFRICA 420
20 COMPETITIVE LANDSCAPE 426
20.1 INTRODUCTION 426
20.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 426
20.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN SEPSIS DIAGNOSTICS MARKET 426
20.3 REVENUE ANALYSIS, 2023–2025 428
20.4 MARKET SHARE ANALYSIS, 2025 429
20.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 429
20.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 430
20.5.1 STARS 430
20.5.2 EMERGING LEADERS 430
20.5.3 PERVASIVE PLAYERS 431
20.5.4 PARTICIPANTS 431
20.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 432
20.5.5.1 Company footprint 432
20.5.5.2 Region footprint 433
20.5.5.3 Product footprint 434
20.5.5.4 Technology footprint 435
20.5.5.5 Pathogen type footprint 436
20.5.5.6 Test type footprint 436
20.5.5.7 Method footprint 437
20.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 438
20.6.1 PROGRESSIVE COMPANIES 438
20.6.2 RESPONSIVE COMPANIES 438
20.6.3 DYNAMIC COMPANIES 438
20.6.4 STARTING BLOCKS 438
20.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 439
20.6.5.1 Detailed list of key startups/SMEs 439
20.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 440
20.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 440
20.7 COMPANY VALUATION & FINANCIAL METRICS 441
20.7.1 FINANCIAL METRICS 441
20.7.2 COMPANY VALUATION 441
20.8 BRAND/PRODUCT COMPARISON 442
20.9 COMPETITIVE SCENARIO 443
20.9.1 PRODUCT LAUNCHES & APPROVALS 443
20.9.2 DEALS 444
20.9.3 OTHER DEVELOPMENTS 445
21 COMPANY PROFILES 446
21.1 KEY PLAYERS 446
21.1.1 BIOMÉRIEUX 446
21.1.1.1 Business overview 446
21.1.1.2 Products offered 447
21.1.1.3 Recent developments 448
21.1.1.3.1 Product launches & approvals 448
21.1.1.3.2 Deals 449
21.1.1.3.3 Other developments 449
21.1.1.4 MnM view 450
21.1.1.4.1 Key strengths 450
21.1.1.4.2 Strategic choices 450
21.1.1.4.3 Weaknesses & competitive threats 450
21.1.2 BECTON, DICKINSON AND COMPANY (BD) 451
21.1.2.1 Business overview 451
21.1.2.2 Products offered 452
21.1.2.3 Recent developments 453
21.1.2.3.1 Product launches & approvals 453
21.1.2.3.2 Deals 453
21.1.2.3.3 Other developments 454
21.1.2.4 MnM view 454
21.1.2.4.1 Key strengths 454
21.1.2.4.2 Strategic choices 454
21.1.2.4.3 Weaknesses and competitive threats 455
21.1.3 DANAHER 456
21.1.3.1 Business overview 456
21.1.3.2 Products offered 457
21.1.3.3 Recent developments 458
21.1.3.3.1 Deals 458
21.1.3.4 MnM view 458
21.1.3.4.1 Key strengths 458
21.1.3.4.2 Strategic choices 458
21.1.3.4.3 Weaknesses & competitive threats 459
21.1.4 DIASORIN S.P.A. 460
21.1.4.1 Business overview 460
21.1.4.2 Products offered 461
21.1.4.3 Recent developments 462
21.1.4.3.1 Product launches & approvals 462
21.1.4.4 MnM view 462
21.1.4.4.1 Key strengths 462
21.1.4.4.2 Strategic choices 463
21.1.4.4.3 Weaknesses & competitive threats 463
21.1.5 F. HOFFMANN-LA ROCHE LTD. 464
21.1.5.1 Business overview 464
21.1.5.2 Products offered 465
21.1.5.3 Recent developments 466
21.1.5.3.1 Product launches & approvals 466
21.1.5.4 MnM view 466
21.1.5.4.1 Key strengths 466
21.1.5.4.2 Strategic choices 466
21.1.5.4.3 Weaknesses & competitive threats 467
21.1.6 THERMO FISHER SCIENTIFIC INC. 468
21.1.6.1 Business overview 468
21.1.6.2 Products offered 469
21.1.7 BRUKER CORPORATION 470
21.1.7.1 Business overview 470
21.1.7.2 Products offered 471
21.1.7.3 Recent developments 472
21.1.7.3.1 Product launches & approvals 472
21.1.7.3.2 Other developments 472
21.1.8 ABBOTT 473
21.1.8.1 Business overview 473
21.1.8.2 Products offered 474
21.1.9 SYSMEX CORPORATION 475
21.1.9.1 Business overview 475
21.1.9.2 Products offered 476
21.1.9.3 Recent developments 477
21.1.9.3.1 Deals 477
21.1.10 SIEMENS HEALTHINEERS AG 478
21.1.10.1 Business overview 478
21.1.10.2 Products offered 479
21.1.11 QIAGEN 480
21.1.11.1 Business overview 480
21.1.11.2 Products offered 481
21.1.11.3 Recent developments 482
21.1.11.3.1 Product launches & approvals 482
21.1.12 SEEGENE INC. 483
21.1.12.1 Business overview 483
21.1.12.2 Products offered 484
21.1.12.3 Recent developments 484
21.1.12.3.1 Product launches & approvals 484
21.1.13 PHC HOLDINGS CORPORATION 485
21.1.13.1 Business overview 485
21.1.13.2 Products offered 487
21.1.14 QUIDELORTHO CORPORATION 488
21.1.14.1 Business overview 488
21.1.14.2 Products offered 490
21.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 491
21.1.15.1 Business overview 491
21.1.15.2 Products offered 492
21.2 OTHER PLAYERS 493
21.2.1 EKF DIAGNOSTICS HOLDINGS PLC 493
21.2.2 INFLAMMATIX, INC. 494
21.2.3 BODITECH MED INC 494
21.2.4 ALIFAX S.R.L. 495
21.2.5 ADVANDX (OPGEN) 495
21.2.6 FUJIREBIO 496
21.2.7 IMMUNEXPRESS 496
21.2.8 RESPONSE BIOMEDICAL CORPORATION 497
21.2.9 DEEPULL DIAGNOSTICS S.L. 497
21.2.10 SEKISUI DIAGNOSTICS 498
22 RESEARCH METHODOLOGY 499
22.1 RESEARCH DATA 499
22.2 SECONDARY DATA 500
22.2.1 LIST OF SECONDARY SOURCES 500
22.2.2 KEY DATA FROM SECONDARY SOURCES 501
22.2.3 PRIMARY DATA 501
22.2.3.1 List of primary sources 502
22.2.3.2 Key data from primary sources 503
22.2.3.3 Key industry insights 504
22.2.3.4 Breakdown of primary interviews 504
22.3 MARKET SIZE ESTIMATION 505
22.3.1 TOTAL MARKET SIZE: SEPSIS DIAGNOSTICS MARKET 505
22.3.2 BOTTOM-UP APPROACH 505
22.3.2.1 Approach 1: Revenue estimation of key players 505
22.3.2.2 Approach 2: Study of annual reports and investor presentations 506
22.3.2.3 Approach 3: Primary interviews 506
22.3.2.4 Growth forecast 506
22.3.2.5 CAGR projections 507
22.3.3 TOP-DOWN APPROACH 508
22.4 DATA TRIANGULATION 508
22.5 RESEARCH ASSUMPTIONS 509
22.5.1 STUDY ASSUMPTIONS 509
22.5.2 PARAMETRIC ASSUMPTIONS 510
22.5.3 GROWTH RATE ASSUMPTIONS 510
22.6 RESEARCH LIMITATIONS 511
22.7 RISK ASSESSMENT 511
23 APPENDIX 512
23.1 DISCUSSION GUIDE 512
23.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 517
23.3 CUSTOMIZATION OPTIONS 519
23.4 RELATED REPORTS 519
23.5 AUTHOR DETAILS 520